Device Trial Radar · NCT01117779
Tracking Renal Tumors After Cryoablation Evaluation
Last checked: Nov 19, 2026Latest source record: Jan 19, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
246
Actual
Start
Jul 9, 2010
Primary completion
Nov 24, 2020
Study completion Nov 24, 2020
Sponsor
- Lead sponsor
- Boston Scientific CorporationPublic (BSX)
- Sponsor type
- Industry
- First posted
- May 5, 2010
Design
- Study type
- Observational
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
TRACE is an observational, open-label, single-arm, multi-center registry of subjects who have undergone renal lesion cryoablation per their physician's standard of care. Patients 18 years of age or older who have been determined to be an appropriate candidate for cryoablation will be offered enrollment into the registry. Subjects will be observed for five years from the date of their cryoablation procedure.
Conditions
- Kidney Neoplasms
Interventions
CryoablationDevice
Cryoablation (freezing) with Galil Medical cryoablation systems and needles under imaging guidance
Primary outcomes
What the sponsor says the trial is designed to measure.
- Changes in Lesion SizeTime frame: Baseline and months 6, 12, 24, 36, 48 and 60
- Renal Function StatusTime frame: Baseline and months 6, 12, 24, 36, 48 and 60
- Hospital StayTime frame: Average duration of 2 days or longer
6 more outcomes with a free account
Locations
7 sites in 1 country. Site status is shown where the registry gives one.
University of California Irvine
Orange, California
Kaiser Permanente
Denver, Colorado
University of Kentucky
Lexington, Kentucky
4 more study sites with a free account
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.